retinal arterial macroaneurysm
Conditions
Interventions
anti-VEGF group:After the initial intravitreal injection of anti-VEGF medication (Conbercept 0.5mg), monthly treatments will be administered based on the retreatment criteria in a pro re nata (PRN) tr
Laser group:To use the traditional laser method
Sponsors
Eye and ENT Hospital of Fudan University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Patients with exudative retinal macroaneurysms (with subfoveal or interretinal effusion, hard exudation, or bleeding) requiring anti-VEGF therapy identified by fluorescence angiography; 2) The symptoms of vision loss attributed to macular edema or hemorrhage; 3) Duration less than 6 months; 4) BCVA >=19 ETDRS letters (Snellen visual acuity 20/400); 5) CRT > 250µm on OCT examination, with macular edema or subretinal fluid; 6) No opacities in the media affecting fundoscopy and no pupillary constriction.
Exclusion criteria
Exclusion criteria: 1) Patients with quiescent retinal artery macroaneurysm (without macular edema or leakage).; 2) Patients with severe vitreous or subretinal hemorrhage and/or secondary macular hole requiring vitrectomy; 3) Patients with active periocular or ocular inflammation in either eye; 4) Presence of any macular disease at baseline that the investigator considers may impact visual recovery; 5) Patients with a history of other diseases causing macular edema; 6) Treatment eyes that have received any prior treatment for macular edema; 7) History of or current uncontrolled glaucoma in either eye; 8) Patients with type I or type II diabetes. 9) History of systemic use of anti-VEGF drugs within the past 6 months prior to screening; 10) Patients with severe asthma, allergies or systemic diseases who cannot undergo fluorescein angiography (FFA) or intravitreal injections; 11) Poorly controlled blood pressure in patients; 12) In the past 6 months prior to screening, patients with severe cardiovascular events such as myocardial infarction, cerebral infarction, active disseminated intravascular coagulation, or marked bleeding tendencies; 13) Patients diagnosed with systemic immunological diseases requiring treatment; 14) Patients currently participating or having participated in other relevant clinical trials in the past 6 months; 15) Patients who refuse or are unable to attend follow-up visits for various reasons; 16) Women of childbearing potential not using effective contraception, pregnant or breastfeeding women. 17) Patients with active psychiatric disorders or other psychological conditions affecting their ability to sign an informed consent form and understand the study; 18) Patients who refuse to sign the informed consent form.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Tumor size;Vascular density ;Best corrected visual acuity;Central retinal thickness; | — |
Countries
China
Contacts
Public ContactWei Liu
Eye and ENT Hospital of Fudan University
Outcome results
None listed